【レポートの概要（一部）】
1. Report Overview
1.1 Overview of the Next-Generation Biologics Market
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Main Questions Answered by This Analytical Study
1.5 Who is This Report For?
1.6 Methodology
1.7 Frequently Asked Questions (FAQ)
1.8 Associated Reports
1.9 About Visiongain
2. Introduction to Next-Generation Biologics
2.1 Brief History of Biological Drug Development
2.1.1 Limitations of Present-Generation Biological Drugs
2.2 The Promise of Next-Generation Biologics
2.2.1 Defining Next-Generation Biologics
2.2.1.1 A Definition of Regenerative Medicine
2.2.1.2 Extending Half-Life: Pegylation and Other Novel Strategies
3. World Next-Generation Biologics Market: Outlook and Forecast 2016-2026
3.1 The Next-Generation Biologics Market 2015
3.1.1 Development of the Next-Generation Biologics Market 2008-2015
3.1.2 Rising Demand for Biological Therapies
3.1.3 Next-Generation Drugs as a Share of the Biologics Market 2015
3.1.4 Main Sectors of the Next-Generation Biologics Market: Antibodies and Regenerative Medicine Lead the Way
3.1.5 Leading Companies in the Next-Generation Biologics Market 2015
3.2 The Next-Generation Biologics Market 2016-2026
3.2.1 Growth Drivers for Biological Drug Revenues 2016-2026
3.2.2 The Next-Generation Biologics Market Forecast 2016-2026
3.2.3 Product Launches in All Sectors to Drive Market Growth 2016-2026
3.2.4 Next-Generation Biologics: Market Restraints 2016-2026
3.2.5 Rising Market Shares for Next-Generation Insulins 2016-2026
4. Leading National Submarkets for Next-Generation Biologics 2016-2026
4.1 Leading National Submarkets for Next-Generation Biologics, 2015
4.1.1 National Submarket Forecasts 2016-2026
4.1.2 How Will National Submarket Shares Change to 2026?
4.2 Rising Disease Incidence in Important Markets 2016-2026
4.3 Approval of Next-Generation Biologics in Leading National Submarkets
4.4 The US Will be the Largest Submarket for Next-Generation Biologics 2016-2026
4.4.1 US Submarket Forecast 2016-2026
4.5 Next-Generation Biologics in Japan 2016-2026
4.5.1 National Expertise in Stem Cell Research
4.5.2 Japanese Submarket Forecast 2016-2026
4.6 Next-Generation Biologics in Leading EU Countries 2016-2026
4.6.1 Regenerative Medicine Development in the EU
4.6.2 Market Access for Next-Generation Biologics in the EU
4.6.3 Germany: Submarket Forecast 2016-2026
4.6.4 France: Submarket Forecast 2016-2026
4.6.5 UK: Submarket Forecast 2016-2026
4.6.6 Italy and Spain: Submarket Forecasts 2016-2026
4.7 Next-Generation Biologics in Emerging Markets 2016-2026
4.7.1 Next-Generation Biologics Development in Emerging Countries
4.7.2 Chinese Submarket Forecast 2016-2026
4.7.3 Indian Submarket Forecast 2016-2026
5. Next-Generation Antibodies: Submarket Outlooks 2016-2026
5.1 Strategies for Improving Antibody Therapies
5.1.1 Antibody-Drug Conjugates: Targeted Cytotoxic Therapies
5.1.2 Engineering Antibodies for Improved Potency
5.1.3 Bispecific Antibodies
5.2 Next-Generation Antibody Therapy Submarket
5.3 Next-Generation Antibody Therapy Submarket 2016-2026
5.3.1 Strong Revenue Growth for Next-Generation Antibodies 2016-2026
5.3.2 Blockbuster Potential Will Drive Growth to 2026: Kadcyla, Adcetris and Cosentyx
5.3.3 Next-Generation Antibodies: Submarket Restraints 2016-2026
5.4 Antibody-Drug Conjugates (ADC) Submarket 2016-2026
5.4.1 Antibody-Drug Conjugates Submarket Forecast 2016-2026
5.4.1.1 Kadcyla and Adcetris: Revenue Forecast 2016-2026
5.4.2 What Will Drive Growth for ACDs to 2026?
5.4.3 A Long Pipeline of ADCs in Clinical Development
5.4.3.1 CMC544 (Pfizer): NHL Development Halted but Trials in ALL Continue
5.4.3.2 NKTR-102 (Nektar Therapeutics): Phase III for Metastatic Breast Cancer
5.4.3.3 CDX-011: Potential for Accelerated Approval in Breast Cancer
5.5 Engineered Antibodies Submarket 2016-2026
5.5.1 Engineered Antibodies Submarket Forecast 2016-2026
5.5.1.1 Gazvya Will Lead the Submarket in 2026
5.5.2 Portfolio Management to Drive Growth 2016-2026
5.5.3 Engineered Antibodies Pipeline 2016
5.5.3.1 Benralizumab (MedImmune/Kyowa Hakko Kirin)
5.6 Bispecific Antibodies Submarket 2016-2026
5.6.1 Bispecific Antibodies Submarket Forecast 2016-2026
5.6.2 Bispecific Antibodies: Submarket Drivers and Restraints 2016-2026
5.6.3 One New Approval and Two Phase II Bispecific Antibodies in 2016
5.6.3.1 Blincyto (Amgen): The Second Approved Bispecific Antibody
6. Antibody Fragments and Novel Antibody-like Drugs: Commercial Potential 2016-2026
6.1 Next-Generation Antibody Fragments: Beyond Fab Fragments
6.1.1 Antibody-Like Proteins Mimic Antibody Therapies
6.1.2 There are Advantages to Using Fragments and Novel Scaffolds
6.2 Antibody Fragment and ALP Submarket 2016-2026
6.2.1 Antibody Fragment and ALP Submarket Forecast 2016-2026
6.2.2 Pharma is Investing Strongly in Antibody Fragments and ALPs
6.2.3 Limited Late-Stage R&D Pipeline to Restrain Growth to 2026
6.3 Outlook for Next-Generation Antibody Fragments 2016-2026
6.3.1 Next-Generation Antibody Fragment Submarket Forecast 2016-2026
6.3.2 One Platform Leads the Pipeline in 2016
6.3.2.1 Three Nanobodies in Development for Rheumatoid Arthritis
6.3.2.2 Caplacizumab (Ablynx): Targeting an Orphan Indication
6.4 The Antibody-Like Protein Submarket 2016-2026
6.4.1 Antibody-Like Protein Submarket Forecast 2016-2026
6.4.2 Four ALPs in Clinical Development in 2016
6.4.2.1 Abicipar Pegol (Allergan/Molecular Partners): Development of the Lead Clinical ALP Delayed
6.5 Will Next-Generation Immunotoxins Change the Market to 2026?
6.5.1 Challenges With First Generation Immunotoxins
6.5.2 Fusion Protein Conjugates: Pipeline 2016
6.5.2.1 Moxetumomab Pasudotox
6.5.3 Humanised Immunotoxins
6.5.3.1 Using Granzyme B in Immunotoxins
6.5.3.2 Immunornases: A Future Development Opportunity for Immunotoxins
7. Next-Generation Insulin Submarket: Outlook 2016-2026
7.1 Strategies for Next-Generation Insulin Development
7.1.1 Reformulating Insulin for Convenient Administration
7.1.1.1 Oral Insulin
7.1.1.2 Inhaled Insulin
7.1.1.3 Exubera: A Failed Attempt at Reformulated Insulin
7.2 Next-Generation Insulin Submarket 2016-2026
7.2.1 Tresiba: Approved in the EU and Japan
7.2.1.1 Tresiba: Revenue Forecast 2016-2026
7.3 Next-Generation Insulin Submarket 2016-2026
7.3.1 Next-Generation Insulin Submarket Forecast 2016-2026
7.3.2 Product Launches in the US and EU Will Drive Submarket Growth 2016-2026
7.3.3 Next-Generation Insulin Submarket Restraints 2016-2026
7.3.3.1 Biosimilar Insulins are Available Since 2015
7.4 Oral Insulin Submarket 2016-2026
7.4.1 Oral Insulin Submarket Forecast 2016-2026
7.4.2 Oral Insulin: Submarket Drivers and Restraints 2016-2026
7.4.3 A Limited Clinical-Stage Pipeline for Oral Insulin 2016
7.4.3.1 Oramed Pharmaceuticals: Oral Insulin in Phase II
7.4.3.2 Oshadi Icp: Phase II Currently Recruiting
7.4.3.3 IN-105: Biocon Partners with Bristol-Myers Squibb for Development
7.4.3.4 Diabetology: Multiple Deals Signed for Emerging Markets
7.4.3.5 Novo Nordisk: NN-1953
7.5 Ultra-Rapid Acting Insulin Submarket 2016-2026
7.5.1 Ultra-Rapid Acting Insulin Submarket Forecast 2016-2026
7.5.1.1 Will Inhaled Insulins Drive Revenue Growth to 2026?
7.5.2 Other Submarket Drivers and Restraints 2016-2026
7.5.3 Ultra-Rapid Acting Insulin Pipeline 2016
7.5.3.1 FlAsp (Novo Nordisk)
7.5.3.2 Adocia: Eli Lilly Opts to Discontinue Partnership
7.5.3.3 Halozyme Therapeutics
7.5.3.4 Biodel: Multiple Ultra Rapid Acting Candidates
7.5.3.5 Afrezza: Inhaled Insulin Nearing the Market
7.5.3.6 Adagio: A Second-Generation Inhaled Insulin
7.6 Ultra-Long Acting Insulin Submarket 2016-2026
7.6.1 Ultra-Long Acting Insulin Submarket Forecast 2016-2026
7.6.2 Revenue Growth Driven by Uptake of Tresiba
7.6.3 Ultra-Long Acting Insulin Pipeline 2016
7.6.3.1 Toujeo: Sanofi’s Next-Generation Insulin Analogue
7.6.3.2 LY2605541 (Eli Lilly)
7.6.3.3 LAPS-Insulin
8. Next-Generation Developments for Other Recombinant Proteins 2016-2026
8.1 Defining Next-Generation for Other Recombinant Protein Sectors
8.1.1 Next-Generation Interferon Beta: Plegridy Revenue Forecast 2016-2026
8.1.1.1 Plegridy May Compete With Other Long-Acting Interferon Beta Therapies 2016-2026
8.1.2 Next-Generation G-CSF: Teva Expands its Filgrastim Franchise
8.1.2.1 Other Clinical-Stages Advances in Filgrastim Therapy 2016
8.2 Next-Generation Recombinant Coagulation Factors 2016-2026
8.2.1 Next-Generation Recombinant Coagulation Factors Submarket Forecast 2016-2026
8.2.2 Submarket Drivers and Restraints 2016-2026
8.2.3 Clinical Pipeline for Recombinant Coagulation Factors 2016-2026
8.2.3.1 Fused Factors: Biogen Idec’s Eloctate and Alprolix
8.2.3.2 Baxter’s BAX 855
8.2.3.3 CSL Behring’s rlX-FP: Albumin-Bound Coagulation Factors
8.2.3.4 Bayer’s BAY94-9027
8.2.3.5 Novo Nordisk’s N8-GP for Haemophilia A
8.2.3.6 Novo Nordisk’s N9-GP for Haemophilia B
8.2.4 Gene Therapy as a New Treatment Option for Haemophilia
8.3 Next-Generation Growth Hormones 2016-2026
8.3.1 Next-Generation Growth Hormone Submarket Forecast 2016-2026
8.3.2 Brand Loyalty Will Restrain Uptake of Next-Generation Hormone 2016-2026
8.3.3 Long-Acting Growth Hormones
8.3.3.1 Biopartners/LG Life Sciences: The First Long-Acting Growth Hormone
8.3.3.2 Prolor Biotech/OPKO Health
8.3.3.3 Novo Nordisk: Looking to Extend its Market-Leading Position
8.3.3.4 Versartis: XTEN Technology for Half-Life Extension
8.3.4 Reformulated Growth Hormones: Offering Convenient Dosing for Paediatric Patients
8.3.4.1 Critical Pharmaceuticals: Nasal Delivery of Somatropin
9. Regenerative Medicine: Commercial Outlook 2016-2026
9.1 The Regenerative Medicine Submarket in 2015
9.1.1 Defining Regenerative Medicine
9.2 The Regenerative Medicine Submarket: Revenue Projections 2016-2026
9.2.1 Stem Cell and Gene Therapy Launches to Drive Growth 2016-2026
9.3 The Stem Cell Therapies Submarket 2016-2026
9.3.1 Prochymal (Mesoblast) for GvHD
9.3.1.1 The Future for Prochymal: Approval in Crohn’s Disease?
9.3.1.2 A Note on Stem Cell Transplants
9.3.2 Stem Cell Therapies Submarket Forecast 2016-2026
9.3.3 Stem Cell Therapies: Submarket Drivers and Restraints 2016-2026
9.3.3.1 Will iPSCs Prove Effective for Stem Cell Therapy?
9.3.4 Stem Cell Therapies Late-Stage Pipeline 2016
9.3.4.1 Cx601 (TiGenix)
9.3.4.2 Mesoblast: Mesenchymal Stem Cell Therapies
9.3.4.3 Baxter Pharmaceuticals: A Leading Cardiovascular Candidate
9.3.4.4 StemEx (Gamida Cell)
9.4 Outlook for Tissue Engineering 2016-2026
9.4.1 Two Sectors Lead the Market: Wound and Cartilage Repair
9.4.1.1 Apligraf Leads the Wound Repair Submarket
9.4.1.2 Organogenesis Markets Apligraf and Dermagraft from 2014
9.4.2 Tissue Engineering Submarket Forecast 2016-2026
9.4.3 Tissue Engineering: Submarket Drivers and Restraints 2016-2026
9.4.4 Future Developments in Cartilage Repair: Pipeline 2016
9.4.5 Organ Repair and Engineering: The Next Step in Tissue Engineering?
9.4.5.1 Engineered Skin
9.4.5.2 Engineered Veins
9.4.5.3 Organ Transplant: A Long-Term Tissue Engineering Opportunity
9.5 The Gene Therapies Submarket 2016-2026
9.5.1 Glybera Approved and Set for Launch in the EU
9.5.2 Gene Therapies Submarket: Revenue Projections 2016-2026
9.5.3 Glybera’s Approval Driving Submarket Growth Since 2014
9.5.4 There are More Than Five Gene Therapies in Late-Stage Development
9.5.4.1 ProstAtak: Gene Therapy for Prostate Cancer
9.5.4.2 TVEC (Amgen)
9.5.4.3 Generx (Cardium Therapeutics)
9.5.4.4 Spark Therapeutics: Established in 2013 for Ophthalmic Gene Therapy
10. Next-Generation Biologics: Industry Trends 2016-2026
10.1 Next-Generation Biologics: Market Strengths 2016
10.2 Next-Generation Biologics: Market Weakness 2016
10.3 The Next-Generation Biologics Market: STEP Analysis 2016-2026
10.3.1 Social Factors: Rising Disease Incidence and Demands for Convenience
10.3.1.1 Rising Incidence in Cardiovascular Disease, Cancer and Diabetes
10.3.1.2 Next-Generation Biologic Development in Emerging Markets
10.3.2 Technological Developments 2016-2026
10.3.3 Economic Pressures 2016-2026
10.3.3.1 High Drug Costs and Healthcare Spending
10.3.3.2 Limited Commercial Potential in Emerging Markets?
10.3.4 Political Issues: Regulatory Developments 2016-2026
10.4 Next-Generation Biologics: Development Trends 2016-2026
10.4.1 Improving Patient Convenience
10.4.2 Sustained Release Biologics: Pegylation and Beyond
10.4.3 Therapeutic Focus for Next-Generation Biologics
10.4.4 Next-Generation Biologics as Personalised Medicine
10.5 Manufacturing Challenges and Opportunities for Next-Generation Biologics
10.5.1 Contract Manufacturers Invest to Follow Development Trends
10.6 Commercialising Next-Generation Biologics
10.6.1 Product Lifecycle Management for First Generation Biologics
10.6.2 Proving Benefit in Next-Generation Products
10.6.3 Biosimilars as a Challenger 2016-2026
10.7 Partnering for Next-Generation Biologic Development
10.7.1 The Role of Big Pharma in the Next-Generation Biologics Market
10.7.2 Most Development Platforms Stem from Small Biotechs
11. Research Interviews from Our Survey
11.1 Dr Edwin Moses, CEO, Ablynx
11.1.1 Ablynx
11.1.2 Ablynx’s Pipeline and Nanobody Technology
11.1.3 On Caplacizumab
11.1.4 Challenged with Current Biological Therapies
11.1.5 The Next-Generation Biologics Market, 2016-2026
11.2 Dr Mike Romanos, CEO, Crescendo Biologics
11.2.1 Crescendo Biologics
11.2.2 The Benefits in Antibody Fragment Therapies
11.2.3 Treatment of Inflammation Indications with Antibody Fragments
11.2.4 Crescendo’s Fragment Pipeline
11.2.5 Development and Production Platforms for Antibody Therapies
11.2.6 Crescendo’s Humabody ADCs and Multi-Specific T-Cell Engagers
11.2.7 CB001, A Topical Biologic
11.2.8 The Next-Generation Biologics Market, 2015-2025
11.3 Sorrento Therapeutics Inc. Team: Dr Gunnar Kaufmann, VP of Research; Dr Kouros Motamed, VP, Strategic Alliances and Clinical Communications; George Uy, EVP and CCO
11.3.1 Sorrento Therapeutics Inc.
11.3.2 Sorrento’s Pipeline
11.3.3 Drivers and Restraints for Next-Generation Biologics
11.3.4 The Next-Generation Biologics Market, 2015-2025
11.4 Dr Fredrik Frejd, CSO, Affibody
11.4.1 Affibody
11.4.2 Challenges with Current Biological Therapies
11.4.2.1 Current Half-Life Extension Technologies
11.4.3 The Benefits of Affibodies Over Current Antibody Therapies
11.4.4 Focus on Inflammation and Autoimmune Diseases
11.4.5 Development of SOBI002
11.4.6 Regulatory Challenges with Novel Biologics
12. Conclusions from Our Research and Analysis
12.1 The Next-Generation Biologics Market Will Grow Strongly to 2026
12.2 Next-Generation Antibody Development Will Lead the Market
12.3 New Treatment Regimens Will Drive Demand for Next-Generation Biologics
12.4 Leading Regional Markets
12.5 Challenges Remain in Developing and Commercialising Next-Generation Biologics
【レポート販売概要】
■ タイトル：次世代生物学的製剤の世界市場2016-2026■ 英文：Next-Generation Biologics Market 2016-2026
■ 発行日：2016年5月
■ 調査会社：visiongain
■ 商品コード：VGAIN60626
■ 調査対象地域：グローバル
- シアン化カリウムの世界市場Potassium Cyanide (CAS 151-50-8) Market Research Report 2014 presents comprehensive data on potassium cyanide markets globally and regionally (Europe, Asia, North America etc.) The report includes potassium cyanide description, covers its application areas and related patterns. It overviews potassium cyanide market, names potassium cyanide producers and indicates its suppliers. Besides, the report …
- デジタルプリント壁紙の世界市場：電子写真、インクジェットGlobal Digitally Printed Wallpaper Market: About this market Technavio’s digitally printed wallpaper market analysis considers sales from both electrophotography and inkjet technologies. Our analysis also considers the sales of digitally printed wallpaper in APAC, Europe, North America, South America, and MEA. In 2018, the electrophotography segment had a significant market share, and this trend i …
- マイクログリッドの世界市場：グリッドコネクテッド型、リモート/アイランド型、ハイブリッド型The microgrid market is estimated to reach USD 34.94 Billion by 2022, at a CAGR of 10.9% between 2016 and 2022. Growing demand for scalable and economic grid controls, cheap and clean energy storage options, and shift towards remote grids in the military segment are the factors driving the microgrid market positively. Among the grid-types available, remote grid-type is expected to grow at the high …
- 世界の自動車エアバッグ布市場2015The Global Automotive Airbag Fabric Industry Report 2015 is a professional and in-depth study on the current state of the Automotive Airbag Fabric industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure.The Automotive Airbag Fabric market analysis is provided for the international markets including development …
- 熱伝導性プラスチックの世界市場：PPS、PBT、PA、PC、PEI、PSUThe global thermally conductive plastic market (2015–2020) is estimated to reach USD 757.4 Million by 2020, at a CAGR of 14.3%. The thermally conductive plastics market is driven by increasing demand for LED lights, lightweight heat sinks, electrical vehicles, medical devices, and lightweight automotive vehicles. The thermally conductive plastics include various types of plastics such as polyamide …
- 防腐剤・消毒剤の世界市場：種類別（第4級アンモニウム、塩素）、製品種類別（医療機器消毒剤）、最終用途別、セグメント予測The global antiseptics and disinfectants market size is expected to reach USD 27.99 billion by 2026, according to a new report by Grand View Research, Inc. It is anticipated to expand at a CAGR of 6.7% during the forecast period. Increasing prevalence of Hospital-acquired Infections (HAIs), awareness about home cleanliness and the need for disinfection, and usage of endoscope reprocesses and surgi …
- シームテープの世界市場2019-2023Global Seam Tapes Market: About this market Technavio’s seam tapes market analysis considers sales from both polyurethane (PU) and polyvinyl chloride (PVC). Our analysis also considers the sales of seam tapes in APAC, Europe, North America, South America, and MEA. In 2018, the PU segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such a …
- 紫外線(日光)角化症(Actinic (Solar) Keratosis)：治療薬開発パイプライン動向（2015年上半期版）Actinic (Solar) Keratosis - Pipeline Review, H1 2015 Summary Global Markets Direct’s, ‘Actinic (Solar) Keratosis - Pipeline Review, H1 2015’, provides an overview of the Actinic (Solar) Keratosis’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Actinic (Solar) Keratosis, complete with comparative analysis at various stages, therapeutics asse …
- 欧州主要国の注射器・注射針市場見通し（～2021）EU5 Syringes and Needles Market Outlook to 2021 Summary GlobalData’s new report, "EU5 Syringes and Needles Market Outlook to 2021", provides key market data on the EU5 Syringes and Needles market. The report provides value, in millions of US dollars, volume (in units) and average price data (in US dollars), within market segments - General Syringes and Specialized Syringes. The report also provide …
- 電気シェーバーの世界市場2017-2021About Electric Shaver In the hair removal appliance segment of the personal care appliance market, the demand for electric shavers is rising. Male users dominate the market demand and are followed by female users. Although manual shaving options dominate the shaver market due to their cost advantage, men are increasingly switching to electric alternatives, especially in developed countries. Ease o …
- OEM絶縁材の世界市場：発泡プラスチック、鉱物綿The global OEM insulation market size is projected to reach USD 14.62 Billion by 2021, at a CAGR of 5.83% between 2016 and 2021. The key drivers of the market are growing awareness and stringent regulations for energy efficiency. Moreover, the market is witnessing a moderate growth owing to increasing applications, technological advancements, and growing demand for OEM insulation in Asia-Pacific a …
- Penn Virginia Corporation：石油・ガスの開発・生産動向及びコスト分析- Q2, 2013Penn Virginia Corporation Oil & Gas Exploration and Production Operations and Cost Analysis - Q2, 2013 Summary Penn Virginia Corporation Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an essentia …
- スマートサーモスタットの世界市場：種類別（WiFi、赤外線、Bluetooth、その他）、用途別（分割AC、ウィンドウAC、ポータブルAC、その他）、最終用途別（住宅、商業、工業、その他）The global smart thermostat market is expected to generate revenue worth $1.36 billion in 2019, and is projected to reach $8.78 billion by 2026, to register a CAGR of 26.0% during the forecast period. Smart thermostat is the new kit of advanced technology that connects heating systems to the internet. This provides users the access to switch heating systems through the internet connected devices. …
- 航空機用アクチュエータの世界市場：電子式、電気式、機械式The aircraft actuator market was valued at USD 10.30 Billion in 2015 and is expected to grow at a CAGR of 9.5% between 2016 and 2022. The actuators and electronic components market growth can be directly linked with the growth of the commercial aviation industry. The most significant factor driving the aircraft actuator market is the increasing demand for commercial aircraft globally. Major factor …
- 世界の凝固検査（Coagulation Testing）市場：課題、新技術、競争環境“New Frontiers in Point-of-Care/POC Coagulation Testing: Business Challenges, Emerging Technologies, Competitive Landscape” is Venture Planning Group’s new report, which provides comprehensive analysis of the POC coagulation testing market, including its dynamics, size, growth, regulatory requirements, technological trends, competitive landscape, and emerging opportunities for in …
